linjc16/ctgov huggingface dataset:
The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace Restaurant Setting: an Observational Study

Study Overview
=================
Brief Summary
-----------------
Encouraging individuals to eat fruit and vegetables is difficult. However, recent evidence suggests that using social-based information might help. For instance, it has been shown that if people think that others are eating lots of fruit and vegetables, that they will consume more food to match the 'norm'.The purpose of this study was to determine whether social norm messages could be used to enhance vegetable purchases in workplace restaurants, in an observational study.

Detailed Description
-----------------
In this study the investigators hypothesised that placing posters containing social norm messages promoting vegetable consumption in three workplace restaurants, would increase the purchase of meals with vegetables, and that this effect would be sustained over time. The investigators recruited three restaurants to this study. For two weeks (Pre-intervention phase) the investigators used till receipts to monitor the number of meals sold with or without vegetables at baseline. For the following two weeks (Intervention phase) the investigators placed social norms posters around the three restaurants, while continuing to collect till receipts. After this, the posters were removed, and receipts were monitored for a final two weeks (Post-intervention).

Official Title
-----------------
The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace

Conditions
-----------------
Eating Behaviour

Intervention / Treatment
-----------------
* Other: Social Norms Poster


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Purchase of a meal at one of the restaurants Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Workplace Restaurant Customers<br>1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study) Study consists of three phases: Pre Intervention Intervention Post Intervention All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster. | Other: Social Norms Poster<br>* A poster containing a social norms message: Most people here choose to eat vegetables with their lunch<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of meals containing vegetables |  | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
social norms, healthy eating, vegetables, field study
Causes and Patterns of Anterior Cruciate Ligament Injuries Among Egyptian Population

Study Overview
=================
Brief Summary
-----------------
The aim of work is to detect the patterns and the causes of ACL injury among Egyptian population and to identify its risk factors. Identify the male to female ratio of injuries in our community. To document the patterns and frequencies of associated injuries

Detailed Description
-----------------
The ACL (Anterior Cruciate ligament) is one of the most frequently injured ligaments of the knee, with a prevalence estimated to be 1 in 3000 in the US (greater than 120000 cases annually). ACL injury frequently affects young, active individuals. It is also frequently associated with other structural injuries in the Knee joint like meniscal tears and multi-ligamentous injuries. ACL injury leads to increased laxity in the knee, predispose the knee to subsequent injuries and early onset osteoarthritis of the knee. Sports related trauma is the commonest cause of ACL rupture. Females are reported to have 2 to 10-fold higher risk of injury than males playing the same sport. According to previous studies at Assuit University Hospital the impression was that the ACL injuries are more common in males than females. Additionally, non-sports injuries like motor cycle accidents and domestic injuries are expected to be a major cause of ACL rupture, besides sports injuries, among Egyptian population.

Official Title
-----------------
Causes and Patterns of ACL Injuries Among Egyptian People

Conditions
-----------------
ACL Injury

Intervention / Treatment
-----------------
* Other: research questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with confirmed ACL injury Exclusion Criteria: Patients with ACL injury associated with fracture at the same limb

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: research questionnaire|Patient personal data History taking clinical knee examination|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patterns of ACL injuries among Egyptian population | Detection of patterns of ACL injuries among 500 Egyptian patient older than 18 years old and younger than 60 years old e.g valgus stress, faulty landing and whether the injury is sport related or not through a validated research questionnaire | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACL injury, non sport causes, Egyptians
LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

Study Overview
=================
Brief Summary
-----------------
Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Detailed Description
-----------------
Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients. This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Official Title
-----------------
LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - clinical diagnosis of lung cancer (C34 in MKN classification) Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | Time from randomization until death from any cause | 60 months of follow-up | 
| Progression-free survival (PFS) | Time from randomization until disease progression or death | any treatment during 60 months of follow-up | 
| Time to treatment discontinuation (TTD) | time from starting a medication until treatment discontinuation or death | any treatment during 60 months of follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to next treatment (TTNT) | Time from end of primary treatment to institution of next therapy | 60 months of follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, bronchogenic carcinoma, diagnosis, treatment, non-interventional
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.

Official Title
-----------------
Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients

Conditions
-----------------
Thyroid Neoplasms

Intervention / Treatment
-----------------
* Drug: I131
* Drug: I123


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with differentiated thyroid cancer recently underwent total thyroidectomy (within 6 months) pathological criteria T1bN0 : Tumor size 1-2cm with no microscopic extension with multifocality (within three foci) T3N0 : Tumor size <=2cm with microscopic extension (less than strap muscle) T1-3N1a : 3 or less micrometastatic lymph node Exclusion Criteria: differentiated thyroid cancer with aggressive variant, poorly differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer gross extension (strap muscle or more) thyroid cancer with distant metastasis previous remote history of thyroid cancer surgery history of cervical external beam radiation therapy previous history of comorbid cancer within 5 years renal insufficiency (Ccr <30ml/min) women with pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: low dose RAI<br>Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue. | Drug: I131<br> <br> * Other names: low dose RAI;|
| Sham Comparator: diagnostic RAI<br>Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan. | Drug: I123<br> <br> * Other names: diagnostic RAI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical Remission Rate |  | within 1 year since first thyroid hormone withdrawal regardless of radioactive iodine administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
radioactive iodine therapy, ablation, thyroid cancer
A Genetic Analysis of Usher Syndrome in Ashkenazi Jews

Study Overview
=================
Brief Summary
-----------------
Hearing loss and loss of vision can be very harmful to the well-being and life of people who suffer from them. Usher syndrome is the name of a disease where people have both hearing loss and visual loss. In fact more than half of people who are deaf and blind have Usher syndrome. In this study we are trying to find the causes of all types of Usher syndrome and to learn more about how the eyes and ears work. Usher syndrome is caused by changes in our genes that lead to mistakes in the functioning of our eyes and ears. We may conduct hearing tests called audiograms to test hearing and a vision test called an electroretinogram (ERG) to test how well the retina (the part of your eye that senses light) is working on participants in the study. From these tests we can tell what kind of Usher syndrome a participant may have. We will then get DNA from participants by drawing blood. The DNA will be studied, along with DNA from members of the participant's family and other families, to try to find the gene that is causing Usher syndrome in the participant. Once the gene is found we will be able to study it to learn more about how the eyes and ears work. If a subject has already been diagnosed we may just need copies of their medical records and blood can be drawn locally. In order to increase the power of the study and the likelihood of detecting relevant genes participants will be taken from the Ashkenazi Jewish population group only. This will make it much easier to find the genes.

Official Title
-----------------
A Genetic Analysis of Usher Syndrome in Ashkenazi Jews

Conditions
-----------------
Usher Syndrome, Retinitis Pigmentosa, Congenital Hearing Impairment

Intervention / Treatment
-----------------
* Procedure: Audiogram
* Procedure: Electroretinogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Any Ashkenazi Jewish individual with combined hearing and visual loss that is or may be any type of Usher syndrome, or a family member of said individual. Exclusion criteria: Any individual who is not an Ashkenazi Jew or does not have combined hearing and visual loss or whose disease has been previously determined not to be Usher syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Audiogram|nan|
|Procedure: Electroretinogram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Greatest International Antiinfective Trial With Avelox

Study Overview
=================
Brief Summary
-----------------
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Official Title
-----------------
GIANT - Greatest International Antiinfective Trial With Avelox®

Conditions
-----------------
Bronchitis, Chronic, Bronchial Diseases

Intervention / Treatment
-----------------
* Drug: Moxifloxacin (Avelox, BAY12-8039)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin Exclusion Criteria: Exclusion criteria must be read in conjunction with the local product information

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Moxifloxacin (Avelox, BAY12-8039)<br>* AECB patients under daily life treatment receiving moxifloxacin according to the local product information.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice |  | During documentation at baseline and at at least one short-term follow-up visit; at maximum two short-term (within ca. 14 days) and two long-term follow-up visits (after ca. 6 and 12 months). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Course of symptom relief |  | During documentation of up to two short-term follow-up visits (within ca. 14 days) | 
| Speed of return to normal daily life activities |  | During documentation of the last short-term follow-up visit (after ca. 14 days) | 
| Adverse events collection |  | Throughout the entire study, whenever Adverse Events occur | 
| Evaluation of frequency of new exacerbations |  | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) | 
| Progression of chronic respiratory disease |  | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Interventional, Observational, NIS, Moxifloxacin, MXF, Avelox, AECB
The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire

Study Overview
=================
Brief Summary
-----------------
Oral allergy syndrome is a type of food allergy which mainly affects people with springtime hay fever. It is caused by a cross-reaction, between antibodies to pollens, usually birch tree pollen, and allergens in many different plant foods. It is characterised by symptoms of itching and/or swelling in the mouth and/or throat when eating certain fruits vegetables and nuts. Many of the allergens causing OAS are destroyed by heat, making allergy testing using traditional allergen extracts unreliable. Prick testing or challenging with fresh foods is more reliable, but time consuming, inconvenient and largely unavailable. Pilot study results suggest the characteristic symptoms and foods involved in OAS allow accurate diagnosis using clinical history alone, which forms the basis for the hypothesis of this proposal that OAS can be diagnosed accurately by use of a validated questionnaire alone. The diagnostic questionnaire (PFSDQ), revised from the results of the pilot study, will be tested against two reference test methods, the gold standard of oral food challenge, and the 'platinum standard' of diagnosis made by a medical expert based on history, skin prick testing and oral food challenge. This is not an epidemiological study but with no published studies on OAS in a UK population, this study will also provide some information on the prevalence of OAS in those with springtime hayfever in the UK.

Official Title
-----------------
The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire

Conditions
-----------------
Food Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptoms of seasonal allergic rhino-conjunctivitis with/without seasonal asthma from March to May Exclusion Criteria: below the age of 18 years, had poorly controlled concomitant asthma (Forced Expiratory Volume in one second (FEV1) <70% predicted), any significant pre-existing medical condition, were pregnant or required β-blocking agents, H1-receptor antagonists or glucocorticosteroids on a continuous basis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The validation of the OAS diagnostic questionnaire (PFSDQ) against accepted standard methods of diagnosis. |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The characterisation of the pollen and aeroallergen sensitivities of those diagnosed with roal allergy syndrome |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral, Allergy, Syndrome, Food, Pollen
A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.

Detailed Description
-----------------
Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.

Official Title
-----------------
A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease

Conditions
-----------------
Graft vs Host Disease

Intervention / Treatment
-----------------
* Biological: Early Decidual stromal cell therapy
* Biological: Late Decidual stromal cell therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute graft versus host disease grade 2-4 or therapy resistant chronic graft versus host disease. Are on calcineurin inhibitor and high dose corticosteroids. Exclusion Criteria: Terminally ill patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Early Decidual Stromal Cells<br>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy. | Biological: Early Decidual stromal cell therapy<br>* Intervention given within 7 days after corticosteroids.<br>|
| Active Comparator: Late Decidual Stromal Cells<br>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy. | Biological: Late Decidual stromal cell therapy<br>* Intervention given after 7 days after corticosteroids.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Actuarial survival at one year after onset of graft versus host disease |  | 12 months after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response at 28 days after onset of graft versus host disease |  | 28 days after inclusion | 
| Side effects |  | Up to 6 months after inclusion | 
| Incidence of severe infections |  | Up to 12 months after inclusion | 
| Disease free survival |  | 12 months after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stem Cell Transplantation, Decidual Stromal Cells